Clinical Trials

710 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT04704934 2026-05-27

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

490 enrolled

Phase 3 Not yet recruiting

Adenocarcinoma, Stomach Neoplasms

NCT07578116 2026-05-27

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

562 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT06819007 2026-05-26

DO-01

582 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

1,157 enrolled 1 FDA

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04622319 2026-05-15

DESTINY-Breast05

1,600 enrolled 1 FDA

HER2-Positive Primary Breast Cancer

NCT06467357 2026-05-14

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT04739761 2026-05-12

DESTINY-B12

506 enrolled 27 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06764875 2026-05-12

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT06989112 2026-05-06

DE-01

Phase 3 Not yet recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07543536 2026-04-22

MEGA-TACT-BC3

132 enrolled

Breast Neoplasms

NCT05950945 2026-04-08

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

250 enrolled

Breast Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

726 enrolled

Stomach Neoplasms

NCT04494425 2026-03-04

DB-06

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled 1 FDA

Breast Neoplasms

NCT06585969 2026-02-12

DISCORDANT

Phase 3 Withdrawn

Breast Neoplasms

NCT06899126 2026-01-08

DESTINY-Lung06

686 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT06174987 2025-10-15

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

50 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA